Ticker: RIGL | Exchange: NASDAQ | Report Date: March 3, 2026, after market close
Rigel Pharmaceuticals, a specialty pharma company that has been transforming from a cash-burning clinical-stage biotech into a profitable royalty and commercial operation, is preparing to report its Q4 and full-year 2025 results today after the close. The company’s revenue trajectory has been remarkable — $115.88M in FY2023, $179.28M in FY2024 (+55%), and an estimated $299.06M for FY2025 (+67%) — driven by escalating TAVALISSE (fostamatinib) royalties for immune thrombocytopenia. With only 5 analysts covering the stock and a consensus Strong Buy rating, tonight’s results will confirm whether Rigel has truly crossed the profitability inflection point — or whether royalty created a one-time earnings spike.
Consensus Estimates
Metric
Q4 FY2025 Estimate
Q4 FY2024 Actual
YoY Change
Revenue
~$75–85M
~$57.6M
+30-48%
EPS
~$1.60–1.80
~$0.8
Significant expansion
Analyst consensus: Strong Buy (5 analysts). Average price target: $43.20 vs. current price of $34.62.
Key Metrics to Watch
1. Full-Year Revenue Versus $299M Estimate
The full-year FY2025 estimate of $299.06M represents a 67% jump from FY2024’s $179.28M. TTM revenue through September 2025 was $282.08M, meaning Q4 needs to deliver approximately $17M above the TTM pace — doable but dependent on milestone timing and royalty payment schedules. A full-year beat confirms the inflection is real; a miss would raise questions about whether the FY2024–2025 jump was driven by one-time payments versus durable royalty streams.
2. Earnings Per Share — Profitability Inflection
FY2025 EPS is estimated at $6.75 versus FY2024’s $0.99 — a near 6x jump that would signal a genuine profitability transition. Rigel reversed a stock split, which compresses the share count to ~18M shares, so EPS numbers are amplified. The key question: is this profitability level sustainable, or was it driven by lumpy milestone receipts that won’t recur?
3. TAVALISSE Royalty Trajectory
TAVALISSE royalties from the U.S. ITP market are Rigel’s most durable revenue stream. Investors will want to see whether royalty volumes are growing (expanded prescriber base, new patient starts, possible label expansion discussions) or plateauing. Any color on TAVALISSE’s performance in adjacent indications (warm autoimmune hemolytic anemia is an ongoing area of interest) would be a meaningful forward catalyst.
4. Operating Expense Discipline
As a lean specialty pharma company, Rigel’s ability to generate earnings depends heavily on keeping SG&A and R&D costs controlled while royalties scale. Any material increase in operating expenses — particularly if tied to new clinical investments without clear near-term milestones — would weigh on the profitability outlook for FY2026.
5. New Licensing / Pipeline Developments
Rigel’s next act beyond TAVALISSE and GAVRETO royalties requires either new pipeline candidates or additional licensing partnerships. Any announcement — even early-stage — of new collaborations, new indications for existing drugs, or milestones from existing agreements would be a catalyst for a company with this level of analyst coverage and a 5-person analyst base that is essentially all-in bullish.
Scenario Analysis
Scenario
Q4 Revenue
FY2025 EPS
Key Driver
Stock Reaction
**Bull**
>$85M
>$7.00 FY
Milestone + strong royalties
+10% to +18%
**Base**
~$75–82M
~$6.50–7.00 FY
Steady royalties, in-line milestones
Flat to +6%
**Bear**
<$70M
<$6.00 FY
Milestone timing shifted, royalties flat
-8% to -15%
Bull case: Q4 revenue clears $85M, the full-year beats $299M comfortably, and management provides FY2026 guidance pointing to continued royalty growth and potential new milestone payments. EPS well above consensus validates the profitability story.
Base case: Q4 lands in the $75–82M range, full-year comes in near $295–305M, and EPS is broadly in line. FY2026 guidance implies modest growth but no acceleration. The stock holds near current levels.
Bear case: Milestone timing shifted out of Q4, causing a revenue miss and a full-year shortfall below $285M. EPS falls below $6.00. Management’s FY2026 commentary is cautious, raising concerns that the FY2025 spike was more milestone-driven than royalty-driven and therefore less sustainable.
Context: Recent Trends
Rigel’s transformation story is genuine but lumpy by nature. Royalty and milestone-based revenues are inherently episodic — a single collaboration payment can swing a quarter dramatically in either direction. The company turned free cash flow positive in FY2024 ($31.44M), a significant milestone after years of cash burn, and the FY2025 profitability inflection appears structural rather than one-off if the TAVALISSE royalty base continues to grow.
With 18 million shares outstanding post-reverse-split and a $34 stock price, Rigel’s market cap is approximately $624M — still modest relative to its revenue run-rate and profitability. The 5-analyst buy consensus and $43 average target suggest room for re-rating if tonight’s results confirm the profit inflection is durable. The key risk is that the FY2026 earnings power is significantly lower than FY2025’s $6.75 EPS estimate if milestone payments don’t repeat and TAVALISSE royalties plateau.
Earnings call begins after market close. Follow AlphaStreet for live transcript coverage and post-earnings results analysis.
Source: StockAnalysis, AlphaStreet Earnings Calendar. Estimates as of March 3, 2026. Consensus figures are approximate and subject to revision.
The post Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect first appeared on AlphaStreet News.
